Table 5 Studies evaluating Endocan
From: Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review
Study | Year | N | Population | Standard Criteria for SIRS/Sepsis | Association with sepsis | Other outcomes |
|---|---|---|---|---|---|---|
Scherpereel et al., [53] | 2006 | 90 | ICU patients with sepsis (63), SIRS (7), healthy controls (20) | 1992 ACCP/SCCM [1] | Higher in sepsis than SIRS or healthy controls (2.71 vs 0.77 and 0.68 ng/ml; P < 0.001);higher in septic shock than severe sepsis and uncomplicated sepsis (6.11 vs 1.97 and 1.95 ng/ml; P < 0.05, P < 0.02) | Endocan on ICU admission higher in nonsurvivors than patients still alive after 10 days (6.98 vs 2.54 ng/ml; P < 0.01), using a cutoff of 6.2 ng/ml, sensitivity and specificity are 75% and 84% respectively. |
Bechard et al., [23] | 2000 | 28 | Patients with septic shock (8), healthy controls (20) | 1992 ACCP/SCCM [1] | Higher in septic shock than healthy controls (7.815 vs 1.081 ng/ml; P = 0.0173) | Â |